SCHEMBL13545280

SCHEMBL13545280

CNc1ccc2c(c1)NC(=O)C(N(C)C)C2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 4/20 0.36
ALDH1A1 P00352 2/20 0.32
MAPT P10636 1/20 0.32
RAB9A P51151 1/20 0.32
GFER P55789 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
DDB1 Q16531 2/20 0.32
CRBN Q96SW2 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.30
GRIN2D O15399 1/20 0.30
GRIN3B O60391 1/20 0.30
GRIN1 Q05586 1/20 0.30
GRIN2A Q12879 1/20 0.30
GRIN2B Q13224 1/20 0.30
GRIN2C Q14957 1/20 0.30
GRIN3A Q8TCU5 1/20 0.30
PYGL P06737 1/20 0.30
PYGM P11217 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13545283 0.85 ALDH1A1 (0.37) TRPV1ALDH1A1MAPTRAB9AGFER
SCHEMBL13545488 0.84 TRPV1 (0.42) TRPV1ALDH1A1MAPTRAB9AGFER
SCHEMBL13545301 0.83 TRPV1 (0.51) TRPV1ALDH1A1MAPTRAB9AGFER
SCHEMBL13382926 0.83 S1PR1 (0.35) TRPV1RAB9ADDB1CRBNMEN1
SCHEMBL13545300 0.83 TRPV1 (0.42) TRPV1ALDH1A1MAPTRAB9AGFER
SCHEMBL13383402 0.81 TRPV1 (0.54) TRPV1MEN1KMT2A
SCHEMBL13382932 0.81 TRPV1 (0.34) TRPV1ALDH1A1MAPTRAB9AGFER
SCHEMBL13545303 0.81 PARP14 (0.36) TRPV1DDB1CRBN
SCHEMBL13545282 0.80 TRPV1 (0.45) TRPV1ALDH1A1MAPTRAB9AGFER
SCHEMBL3595894 0.79 TRPV1 (0.30) TRPV1DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE CCNY, CCND3, NSD3 TRPV1 2518/4885ALDH1A1 1904/4885MAPT 4758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.